Evaluating Benefit of Peptide Based Diet in Obese HEN Patients
Effect of Hypocaloric, High-protein Enteral Formula on Body Weight and Health Outcomes in Obese HEN Patients: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Home Enteral Nutrition (HEN) patient receiving at least 90% of energy needs from enteral nutrition.
- BMI > 30.
- History of stroke.
- Weight stable over the past month.
Exclusion Criteria:
- Diagnosis of cancer undergoing active treatment (chemotherapy, radiation, immunotherapy).
- Life expectancy of less than 6 months.
- Stage IV or higher kidney disease (GFR < 30).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Peptamen Intense in obese home enteral nutrition patients after stroke
Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.
|
An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals.
Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%).
The energy content is 1.0 kcal/mL.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight
Time Frame: Baseline, 3 months
|
Change in body weight, measured in kg
|
Baseline, 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in lean body mass
Time Frame: Baseline, 12 weeks
|
Change in lean body mass, measured as the difference between total body weight and body fat weight reported in percentage
|
Baseline, 12 weeks
|
|
Change in systolic and diastolic blood pressure
Time Frame: Baseline, 12 weeks
|
Change in systolic and diastolic blood pressure, measured in mmHg
|
Baseline, 12 weeks
|
|
Change in HbA1c
Time Frame: Baseline, 12 weeks
|
Change in hemoglobin A1c, measured in percentage
|
Baseline, 12 weeks
|
|
Change in c-peptide
Time Frame: Baseline, 12 weeks
|
Change in c-peptide serum levels, measured in ng/mL
|
Baseline, 12 weeks
|
|
Change in total cholesterol
Time Frame: Baseline, 12 weeks
|
Change in total cholesterol, measured in milligrams (mg) of cholesterol per deciliter (dL) of blood.
|
Baseline, 12 weeks
|
|
Change in HDL
Time Frame: Baseline, 12 weeks
|
Change in HDL, measured in milligrams (mg) of HDL per deciliter (dL) of blood.
|
Baseline, 12 weeks
|
|
Change in LDL
Time Frame: Baseline, 12 weeks
|
Change in LDL, measured in milligrams (mg) of LDL per deciliter (dL) of blood.
|
Baseline, 12 weeks
|
|
Change in triglycerides
Time Frame: Baseline, 12 weeks
|
Change in triglycerides, measured in milligrams (mg) of triglycerides per deciliter (dL) of blood.
|
Baseline, 12 weeks
|
|
Change in percent goal calories provided with enteral nutrition
Time Frame: Baseline, 12 weeks
|
Change in percent goal calories provided with enteral nutrition , measured percent of calorie provided with enteral nutrition from the estimated goal.
|
Baseline, 12 weeks
|
|
Change in percent goal proteins provided with enteral nutrition
Time Frame: Baseline, 12 weeks
|
Change in percent goal proteins provided with enteral nutrition , measured percent of protein provided with enteral nutrition from the estimated goal.
|
Baseline, 12 weeks
|
|
Change in tube feeding tolerance
Time Frame: Baseline, 12 weeks
|
Change in tolerance to tube feeding, measured by follow up questionnaire about symptoms of GI intolerance; namely, diarrhea, constipation, abdominal(stomach/tummy/belly) pain or discomfort, nausea and vomiting.
The scale used will asses the frequency of these symptoms using the following terms: not at all, rarely, sometimes, often, and very often with not at all being least frequent and very often being most frequent presence of the concerning symptom.
|
Baseline, 12 weeks
|
|
Change in hand grip strength
Time Frame: Baseline, 12 weeks
|
Change in hand grip strength, measured by dynamometer.
|
Baseline, 12 weeks
|
|
Change in diabetes medications
Time Frame: Baseline, 12 weeks
|
Change in diabetes medications, measured by capturing any change in diabetes medications (when applicable) in terms of new medications added, or discontinuation or change in doses of current medications.
|
Baseline, 12 weeks
|
|
Change in anti-hypertensive medications
Time Frame: Baseline, 12 weeks
|
Change in hypertension medications, measured by capturing any change in hypertension medications (when applicable) in terms of new medications added, or discontinuation or change in doses of current medications.
|
Baseline, 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Manpreet Mundi, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20-012322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.